Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Biomarkers for Pancreatitis and Its Complications
share announcement

Biomarkers for Pancreatitis and Its Complications

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 5841

Special Issue Editors

Dr. Paulina Dumnicka

E-Mail Website
Guest Editor
Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
Interests: laboratory medicine; acute pancreatitis; biomarkers of inflammation; biomarkers of kidney diseases; acute kidney injury; chronic kidney disease
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Beata Kusnierz-Cabala

E-Mail Website
Guest Editor
Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
Interests: laboratory medicine; acute pancreatitis; biomarkers of inflammation; biomarkers of kidney diseases; acute kidney injury; chronic kidney disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 2012, the revision of the Atlanta classification redefined the severity of acute pancreatitis (AP) and stressed the importance of the early recognition of organ failure related to systemic inflammation and vascular dysfunction. Since then, improved fluid resuscitation and nutritional treatment in line with advancements in imaging techniques and minimally invasive surgery have significantly improved the survival rates of patients with severe AP. During the last decade, the systemic complications of AP (including cardiovascular, lung, and kidney failure) have gained research interest. Epidemiological data on prevalence and mortality rates have been collected, and our understanding of AP pathophysiology has improved, although there is still much work to be performed in this field. The early prediction of the severity of AP, however, remains challenging in clinical practice.

Recently, improved understanding of the pathophysiology of chronic pancreatitis (CP) and advancements in translational research have resulted in the publication of the International Consensus Statements on Early Chronic Pancreatitis. The historical definition of the disease that required “irreversible morphological change” for the diagnosis of CP has been replaced with a mechanistic definition proposed in 2016, allowing for the diagnosis of the disease in its early, potentially reversible stage. International consensus regarding the definition of early CP has not been reached because the presently available diagnostic measures cannot reliably distinguish early CP from other pathologies with overlapping symptoms. CP increases the risk for pancreatic cancer; however, cancer surveillance is only indicated in a highest-risk minority, partially due to a lack of accurate biomarkers.

This Special Issue will include both basic and translational studies on biomarkers of AP and CP. Articles/reviews that advance the knowledge of the early prediction of severe AP and early diagnosis of CP as well as pancreatic cancer are especially of interest.

Dr. Paulina Dumnicka
Prof. Dr. Beata Kusnierz-Cabala
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute pancreatitis
  • recurrent acute pancreatitis
  • chronic pancreatitis
  • pancreatic cancer
  • diagnostic biomarkers
  • biomarkers of severity
  • prognostic biomarkers

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 3540 KiB  
Article
Unraveling the Metabolic Changes in Acute Pancreatitis: A Metabolomics-Based Approach for Etiological Differentiation and Acute Biomarker Discovery
by Greta Dancu, Cristi Tarta, Carmen Socaciu, Felix Bende, Mirela Danila, Roxana Sirli, Ioan Sporea, Bogdan Miutescu and Alina Popescu
Biomolecules 2023, 13(10), 1558; https://doi.org/10.3390/biom13101558 - 22 Oct 2023
Viewed by 1080
Abstract
Acute pancreatitis (AP) remains a challenging medical condition, where a deeper metabolic insight could pave the way for innovative treatments. This research harnessed serum metabolomics to discern potential diagnostic markers for AP and distinguish between its biliary (BAP) and alcohol-induced (AAP) forms. Leveraging [...] Read more.
Acute pancreatitis (AP) remains a challenging medical condition, where a deeper metabolic insight could pave the way for innovative treatments. This research harnessed serum metabolomics to discern potential diagnostic markers for AP and distinguish between its biliary (BAP) and alcohol-induced (AAP) forms. Leveraging high-performance liquid chromatography coupled with mass spectrometry, the metabolic signatures of 34 AP patients were contrasted against 26 healthy participants, and then between different etiologies of AP. The results identified metabolites primarily from glycerophospholipids, glycerolipids, fatty acyls, sterol lipids, and pteridines and derivative classes, with the Human Metabolome Database aiding in classification. Notably, these metabolites differentiated AP from healthy states with high AUROC values above 0.8. Another set of metabolites revealed differences between BAP and AAP, but these results were not as marked as the former. This lipidomic analysis provides an introduction to the metabolic landscape of acute pancreatitis, revealing changes in multiple lipid classes and metabolites and identifying these metabolites. Future research could add and discover new diagnostic biomarkers and therapeutic strategies enhancing the management of acute pancreatitis. Full article
(This article belongs to the Special Issue Biomarkers for Pancreatitis and Its Complications)
►▼ Show Figures

Figure 1

20 pages, 2711 KiB  
Article
Administration of Warfarin Inhibits the Development of Cerulein-Induced Edematous Acute Pancreatitis in Rats
by Katarzyna Konarska-Bajda, Piotr Ceranowicz, Jakub Cieszkowski, Grzegorz Ginter, Agnieszka Stempniewicz, Krystyna Gałązka, Beata Kuśnierz-Cabala, Paulina Dumnicka, Joanna Bonior and Zygmunt Warzecha
Biomolecules 2023, 13(6), 948; https://doi.org/10.3390/biom13060948 - 06 Jun 2023
Cited by 3 | Viewed by 1436
Abstract
Acute pancreatitis (AP) is a severe disease with high morbidity and mortality in which inflammation and coagulation play crucial roles. The development of inflammation leads to vascular injury, endothelium and leukocytes stimulation, and an increased level of tissue factor, which results in the [...] Read more.
Acute pancreatitis (AP) is a severe disease with high morbidity and mortality in which inflammation and coagulation play crucial roles. The development of inflammation leads to vascular injury, endothelium and leukocytes stimulation, and an increased level of tissue factor, which results in the activation of the coagulation process. For this reason, anticoagulants may be considered as a therapeutic option in AP. Previous studies have shown that pretreatment with heparin, low-molecular-weight heparin (LMWH), or acenocoumarol inhibits the development of AP. The aim of the present study was to check if pretreatment with warfarin affects the development of edematous pancreatitis evoked by cerulein. Warfarin (90, 180, or 270 µg/kg/dose) or saline were administered intragastrically once a day for 7 days consecutively before the induction of AP. AP was evoked by the intraperitoneal administration of cerulein. The pre-administration of warfarin at doses of 90 or 180 µg/kg/dose reduced the histological signs of pancreatic damage in animals with the induction of AP. Additionally, other parameters of AP, such as an increase in the serum activity of lipase and amylase, the plasma concentration of D-dimer, and interleukin-1β, were decreased. In addition, pretreatment with warfarin administered at doses of 90 or 180 µg/kg/dose reversed the limitation of pancreatic blood flow evoked by AP development. Warfarin administered at a dose of 270 µg/kg/dose did not exhibit a preventive effect in cerulein-induced AP. Conclusion: Pretreatment with low doses of warfarin inhibits the development of AP evoked by the intraperitoneal administration of cerulein. Full article
(This article belongs to the Special Issue Biomarkers for Pancreatitis and Its Complications)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 315 KiB  
Review
A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present
by Muhammad Begawan Bestari, Ignatius Ronaldi Joewono and Ari Fahrial Syam
Biomolecules 2024, 14(3), 364; https://doi.org/10.3390/biom14030364 - 19 Mar 2024
Viewed by 908
Abstract
Pancreatic cancer (PC) is the most lethal type of cancer; it has the lowest 5-year survival rate among all other types of cancers. More than half of PC cases are diagnosed at an advanced stage due to PC’s insidious and non-specific symptoms. Surgery [...] Read more.
Pancreatic cancer (PC) is the most lethal type of cancer; it has the lowest 5-year survival rate among all other types of cancers. More than half of PC cases are diagnosed at an advanced stage due to PC’s insidious and non-specific symptoms. Surgery remains the most efficacious treatment option currently available, but only 10–20% of PC cases are resectable upon diagnosis. As of now, the sole biomarker approved by the United States Food and Drug Administration (US-FDA) for PC is carbohydrate antigen 19-9 (CA19-9); however, its use is limited for early diagnosis. An increasing number of studies have investigated a combination of biomarkers. Lately, there has been considerable interest in the application of a liquid biopsy, including the utilization of microRNAs (miRNAs), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs). Screening for PC is indicated for high-risk patients; studies on new diagnostic models combined with biomarkers for early detection have also shown promising results in terms of the ability of these models and biomarkers to aid clinicians in deciding on whether to start screening. This review seeks to provide a concise overview of the advancements in relation to existing biomarkers and explore novel strategies for the early detection of PC. Full article
(This article belongs to the Special Issue Biomarkers for Pancreatitis and Its Complications)
23 pages, 2234 KiB  
Review
Circulating Biomarkers Involved in the Development of and Progression to Chronic Pancreatitis—A Literature Review
by Valborg Vang Poulsen, Amer Hadi, Mikkel Parsberg Werge, John Gásdal Karstensen and Srdan Novovic
Biomolecules 2024, 14(2), 239; https://doi.org/10.3390/biom14020239 - 18 Feb 2024
Viewed by 1779
Abstract
Chronic pancreatitis (CP) is the end-stage of continuous inflammation and fibrosis in the pancreas evolving from acute- to recurrent acute-, early, and, finally, end-stage CP. Currently, prevention is the only way to reduce disease burden. In this setting, early detection is of great [...] Read more.
Chronic pancreatitis (CP) is the end-stage of continuous inflammation and fibrosis in the pancreas evolving from acute- to recurrent acute-, early, and, finally, end-stage CP. Currently, prevention is the only way to reduce disease burden. In this setting, early detection is of great importance. Due to the anatomy and risks associated with direct sampling from pancreatic tissue, most of our information on the human pancreas arises from circulating biomarkers thought to be involved in pancreatic pathophysiology or injury. The present review provides the status of circulating biomarkers involved in the development of and progression to CP. Full article
(This article belongs to the Special Issue Biomarkers for Pancreatitis and Its Complications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop